Samira Rasaneh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Samira Rasaneh has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Fariba Johari Daha
Department of Radioisotope, Nuclear science and Technology Research Institute, Tehran 14115-331, Iran ; 2 Department of Medical Physics, School of Medical Sciences, Tarbiat Modares University, Tehran 14115-331, Iran
5 shared publicationsMohammad Hossein Babaei
5 shared publicationsHossein Rajabi
Department of Radioisotope, Nuclear science and Technology Research Institute, Tehran 14115-331, Iran ; 2 Department of Medical Physics, School of Medical Sciences, Tarbiat Modares University, Tehran 14115-331, Iran
4 shared publications- Hossein Rajabi
Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3 shared publications - Maryam-Rahele Dadras
Iran University of Medical Sciences
2 shared publications H Rajabi
1 shared publication
Latest Publications
- 29 February 2016
- Published by Taylor & Francis in Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry
- Vol. 46 (10) , 1450-1454
Synthesis and Biological Evaluation of 99mTc-Chitosan Nanoparticles as a Potential Radiopharmaceutical for Liver Imaging
Nanoparticles are generally cleared by the reticuloendothelial system, taken up by Kupffer cells in liver. This principle can be used for liver imaging. Chitosan is an excellent biocompatible and biodegradable polymer. In this study, the authors synthesized 99mTc-chitosan nanoparticles and evaluated its potential for liver imaging. Chitosan nanoparticles were synthesized and radiolabeled with 99mTc. The labeling efficiency, stability, biodistribution, and imaging study in the normal mice was performed. Biodistribution and imaging studies demonstrated an efficient accumulation of the radiolabeled nanoparticles in the mice liver and indicated the 99mTc-chitosan nanoparticles may be considered as a promising radiopharmaceutical for liver imaging.
- 29 February 2016
- Published by Taylor & Francis in Synthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry
- Vol. 46 (10) , 1450-1454
Synthesis and Biological Evaluation of 99mTc-Chitosan Nanoparticles as a Potential Radiopharmaceutical for Liver Imaging
Nanoparticles are generally cleared by the reticuloendothelial system, taken up by Kupffer cells in liver. This principle can be used for liver imaging. Chitosan is an excellent biocompatible and biodegradable polymer. In this study, the authors synthesized 99mTc-chitosan nanoparticles and evaluated its potential for liver imaging. Chitosan nanoparticles were synthesized and radiolabeled with 99mTc. The labeling efficiency, stability, biodistribution, and imaging study in the normal mice was performed. Biodistribution and imaging studies demonstrated an efficient accumulation of the radiolabeled nanoparticles in the mice liver and indicated the 99mTc-chitosan nanoparticles may be considered as a promising radiopharmaceutical for liver imaging.
- 30 July 2015
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 307 (2) , 1353-1357
The potential of SOCTA as a chelator for radiolabeling of trastuzumab with 99mTc
- 30 July 2015
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 307 (2) , 1353-1357
The potential of SOCTA as a chelator for radiolabeling of trastuzumab with 99mTc
- Open Access
- 1 April 2015
- Vol. 27 (2) , 203-208
Activity estimation in radioimmunotherapy using magnetic nanoparticles
Estimation of activity accumulated in tumor and organs is very important in predicting the response of radiopharmaceuticals treatment. In this study, we synthesized 177Lutetium (177Lu)-trastuzumab-iron oxide nanoparticles as a double radiopharmaceutical agent for treatment and better estimation of organ activity in a new way by magnetic resonance imaging (MRI). 177Lu-trastuzumab-iron oxide nanoparticles were synthesized and all the quality control tests such as labeling yield, nanoparticle size determination, stability in buffer and blood serum up to 4 d, immunoreactivity and biodistribution in normal mice were determined. In mice bearing breast tumor, liver and tumor activities were calculated with three methods: single photon emission computed tomography (SPECT), MRI and organ extraction, which were compared with each other. The good results of quality control tests (labeling yield: 61%±2%, mean nanoparticle hydrodynamic size: 41±15 nm, stability in buffer: 86%±5%, stability in blood serum: 80%±3%, immunoreactivity: 80%±2%) indicated that 177Lu-trastuzumab-iron oxide nanoparticles could be used as a double radiopharmaceutical agent in mice bearing tumor. Results showed that 177Lu-trastuzumab-iron oxide nanoparticles with MRI had the ability to measure organ activities more accurate than SPECT. Co-conjugating radiopharmaceutical to MRI contrast agents such as iron oxide nanoparticles may be a good way for better dosimetry in nuclear medicine treatment.
- 1 April 2015
- Vol. 27 (2) , 203-208
Open AccessActivity estimation in radioimmunotherapy using magnetic nanoparticles
Estimation of activity accumulated in tumor and organs is very important in predicting the response of radiopharmaceuticals treatment. In this study, we synthesized 177Lutetium (177Lu)-trastuzumab-iron oxide nanoparticles as a double radiopharmaceutical agent for treatment and better estimation of organ activity in a new way by magnetic resonance imaging (MRI). 177Lu-trastuzumab-iron oxide nanoparticles were synthesized and all the quality control tests such as labeling yield, nanoparticle size determination, stability in buffer and blood serum up to 4 d, immunoreactivity and biodistribution in normal mice were determined. In mice bearing breast tumor, liver and tumor activities were calculated with three methods: single photon emission computed tomography (SPECT), MRI and organ extraction, which were compared with each other. The good results of quality control tests (labeling yield: 61%±2%, mean nanoparticle hydrodynamic size: 41±15 nm, stability in buffer: 86%±5%, stability in blood serum: 80%±3%, immunoreactivity: 80%±2%) indicated that 177Lu-trastuzumab-iron oxide nanoparticles could be used as a double radiopharmaceutical agent in mice bearing tumor. Results showed that 177Lu-trastuzumab-iron oxide nanoparticles with MRI had the ability to measure organ activities more accurate than SPECT. Co-conjugating radiopharmaceutical to MRI contrast agents such as iron oxide nanoparticles may be a good way for better dosimetry in nuclear medicine treatment.
- 1 January 2015
- Published by Walter de Gruyter GmbH in Biomedical Engineering / Biomedizinische Technik
- Vol. 60 (5) , 485-490
The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibody
Introduction: Herceptin is an expensive humanized antibody used for the treatment of early-stage breast cancers. This antibody can cause cardiotoxicity in some patients. In this study, we evaluated the possibility of increasing the therapeutic efficacy of Herceptin by combining magnetic nanoparticles and a permanent magnet for more accumulation in the tumor site.Methods: Herceptin magnetic nanoparticles (HMNs) were synthesized and some of their characteristics, such as stability, magnetization, particle size by transmission electron microscopy (TEM), and dynamic light scattering (DLS) technique, were measured. The biodistribution study was checked in mice bearing breast tumor with and without a permanent magnet on the position of the tumor. The therapeutic effects of HMNs were considered in this condition.Results: The size distribution of HMNs determined by the DLS technique was 182±7 nm and the average size by TEM was 100±10 nm. The reductions of 81% and 98% in the mean tumor volume for the group that received HMNs with magnetic field were observed at 42 and 45 days after injection, respectively.Conclusion: The good results in mice indicated that Herceptin-loaded iron oxide nanoparticles with external magnetic field have good potential for use in humans as a targeted drug delivery that needs more investigation.
- 1 January 2015
- Published by Walter de Gruyter GmbH in Biomedical Engineering / Biomedizinische Technik
- Vol. 60 (5) , 485-490
The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibody
Introduction: Herceptin is an expensive humanized antibody used for the treatment of early-stage breast cancers. This antibody can cause cardiotoxicity in some patients. In this study, we evaluated the possibility of increasing the therapeutic efficacy of Herceptin by combining magnetic nanoparticles and a permanent magnet for more accumulation in the tumor site.Methods: Herceptin magnetic nanoparticles (HMNs) were synthesized and some of their characteristics, such as stability, magnetization, particle size by transmission electron microscopy (TEM), and dynamic light scattering (DLS) technique, were measured. The biodistribution study was checked in mice bearing breast tumor with and without a permanent magnet on the position of the tumor. The therapeutic effects of HMNs were considered in this condition.Results: The size distribution of HMNs determined by the DLS technique was 182±7 nm and the average size by TEM was 100±10 nm. The reductions of 81% and 98% in the mean tumor volume for the group that received HMNs with magnetic field were observed at 42 and 45 days after injection, respectively.Conclusion: The good results in mice indicated that Herceptin-loaded iron oxide nanoparticles with external magnetic field have good potential for use in humans as a targeted drug delivery that needs more investigation.
- 1 November 2010
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 37 (8) , 949-955
177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer
- 1 November 2010
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 37 (8) , 949-955
177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer
- 1 October 2010
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 68 (10) , 1964-1966
Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines
- 1 October 2010
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 68 (10) , 1964-1966
Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines
- 29 June 2010
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 13 (6) , 2285-2293
MRI contrast agent for molecular imaging of the HER2/neu receptor using targeted magnetic nanoparticles
- 29 June 2010
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 13 (6) , 2285-2293
MRI contrast agent for molecular imaging of the HER2/neu receptor using targeted magnetic nanoparticles
- 17 June 2010
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 53 (9) , 575-579
Synthesis and biodistribution studiesof 177Lu‐trastuzumab as a therapeutic agent in the breast cancer mice model
Trastuzumab is a humanized monoclonal antibody against the HER2 that has the potential to be used as radioimmunotherapy (RIT) agent in treatment of breast cancer. Lutetium‐177 has beta energy suitable for therapy and gamma photons for imaging. We labeled trastuzumab with lutetium‐177 via DOTA as chelator and performed some necessary tests for the first stage in using complex as a RIT agent. Radiochemical purity, immunoreactivity and stability of complex were determined. The biodistribution and imaging studies were determined in mice bearing breast tumor. The radiochemical purity was 94±0.9%. Lutetium‐Trastuzumab showed a good stability at biological condition. The tumor to blood ratio was calculated 3.29(±0.09) after 7 days. The good tumor uptake in biodistribution studies was agreed with gamma camera images after 7 days. The results showed that the new complex could be considered for further evaluation in animals and possibly in humans as a new radiopharmaceutical for use in RIT against breast cancer. Copyright © 2010 John Wiley & Sons, Ltd.
- 17 June 2010
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 53 (9) , 575-579
Synthesis and biodistribution studiesof 177Lu‐trastuzumab as a therapeutic agent in the breast cancer mice model
Trastuzumab is a humanized monoclonal antibody against the HER2 that has the potential to be used as radioimmunotherapy (RIT) agent in treatment of breast cancer. Lutetium‐177 has beta energy suitable for therapy and gamma photons for imaging. We labeled trastuzumab with lutetium‐177 via DOTA as chelator and performed some necessary tests for the first stage in using complex as a RIT agent. Radiochemical purity, immunoreactivity and stability of complex were determined. The biodistribution and imaging studies were determined in mice bearing breast tumor. The radiochemical purity was 94±0.9%. Lutetium‐Trastuzumab showed a good stability at biological condition. The tumor to blood ratio was calculated 3.29(±0.09) after 7 days. The good tumor uptake in biodistribution studies was agreed with gamma camera images after 7 days. The results showed that the new complex could be considered for further evaluation in animals and possibly in humans as a new radiopharmaceutical for use in RIT against breast cancer. Copyright © 2010 John Wiley & Sons, Ltd.
- 1 May 2009
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (4) , 363-369
Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer
- 1 May 2009
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (4) , 363-369
Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer
- 1 January 2009
- Published by Springer Nature in IFMBE Proceedings
- p. 235-236
Iron oxide nanoparticles conjugated with trastuzumab as an immunospecific probe for detecting HER2 antigen
- 1 January 2009
- Published by Springer Nature in IFMBE Proceedings
- p. 235-236
Iron oxide nanoparticles conjugated with trastuzumab as an immunospecific probe for detecting HER2 antigen